#National Institute of Allergy and Infectious Diseases

Abbott researchers found a high proportion of elite HIV controllers in the Democratic Republic of Congo, which could lead to cure insights.

A roll call from team Biden-Harris

The new prevention approach shows promise, but it isn’t heading to the clinic anytime soon.

Here are the researchers who will lead the four networks of HIV trials and what each network will focus on.

While receiving a lifetime achievement award, the infectious disease expert shares memories and insights.

Anthony Fauci, MD, leads U.S. efforts against HIV and COVID-19.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

Products based on broadly neutralizing antibodies could be used in HIV treatment and prevention.

Funding will support the DC Cohort, the “largest citywide study of people living with HIV in the United States.”

The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.

Interim guidance from HIVMA and AIDSinfo covers lab visits, opioid treatment programs, pregnant women and more.

Researchers used a harmless virus to deliver a gene for a broadly neutralizing HIV antibody to cells, which produced the antibody over time.

Conducted in South Africa, it’s one of three major late-stage trials.

For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.

Intravenous administration allowed the marginally effective BCG vaccination to work better in monkeys.